GWS
ITCI

Glassman Wealth Services’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Glassman Wealth Services’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7
Closed -$365 – 2091
2023
Q3 		$365 Buy
7
+2
+40% +$117 ﹤0.01% 1797
2023
Q2 		$317 Buy
+5
New +$312 ﹤0.01% 1728
2022
Q4 		– Sell
-3
Closed – – 2055
2022
Q3 		$0 Sell
3
-13
-81% -$679 ﹤0.01% 2042
2022
Q2 		$1K Buy
+16
New +$907 ﹤0.01% 1587

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glassman Wealth Services's ITCI Position: Q4 2023 in Review

Glassman Wealth Services sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2023, closing a stake of 7 shares — an estimated $365 sold.

Glassman Wealth Services first reported a position in ITCI in Q2 2022 and held it in 4 quarters. The position peaked at $1K in Q2 2022. 333 funds tracked by Wall St. Rank hold ITCI as of Q4 2023.

  • Glassman Wealth Services reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2023 after selling out during the quarter.
  • Glassman Wealth Services sold 7 Intra-Cellular Therapies Inc. shares in Q4 2023, an estimated $365.
  • Glassman Wealth Services first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 4 quarters.
  • Glassman Wealth Services's Intra-Cellular Therapies Inc. position peaked at $1K in Q2 2022.
  • 333 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2023.

Based on Glassman Wealth Services's 13F filing for Q4 2023, filed 12 Feb 2024.